Nifty Pharma Today: Index Performance, Gainers & Losers

Updated: 26 Aug 2026 • 4:06 pm

Posted by:

Nifty Pharma Today: Index Performance, Gainers & Losers

Nifty Pharma closed the session on 26 August 2026 at 26,626.3, up 62.3 points or 0.23% from the previous close of 26,564. The move was positive but measured, showing that the pharma pack finished in the green even though gains were not broad enough to signal a runaway rally. The day featured a healthy mix of winners and losers, with sharp upside in a few key names balancing declines in several other constituents.

For users tracking Nifty Pharma today, the most important takeaway is that the index remained resilient despite visible stock-level divergence. The opening level was 26,567, very close to the previous close, which suggests a relatively stable start. During the session, the index moved between an intraday low of 26,437.15 and an intraday high of 26,764.95 before settling modestly higher. That intraday range shows there was active price discovery inside the sector rather than a straight-line trend.

This article breaks down the full Nifty Pharma performance using verified price and breadth data. It covers the day’s index snapshot, market breadth, complete constituent movement, top gainers, top losers, heavyweight stock action, historical comparison based on the available session data, and the practical signals investors may want to watch next. The analysis is based on available index price action and constituent movement.

Table of Contents

Nifty Pharma Snapshot

Metric	Value
Current Value	26,626.3
Absolute Change	62.3
Percentage Change	0.23%
Opening Value	26,567
Previous Close	26,564
Day High	26,764.95
Day Low	26,437.15
Market Status	Closed
Last Updated	26 August 2026 at 4:00:00 PM IST
Market Trend	Sideways to mildly bullish

The index ended above both its opening level and previous close, which supports a mildly bullish reading for the day. However, the gain was only 0.23%, and market breadth remained mixed. That combination usually points to selective buying rather than broad-based sector enthusiasm. In plain language, Nifty Pharma moved higher, but it did so because some stocks rose strongly enough to offset declines in others.

The intraday high of 26,764.95 and low of 26,437.15 imply a range of 327.8 points. Since the close came closer to the upper half of this band than the lower half, the final hour likely reflected decent support in the sector. At the same time, the index did not finish at the day’s high, which suggests traders were still balancing profit-booking and fresh buying.

Why Nifty Pharma Moved Today

Based on the verified data, the clearest explanation for today’s move is internal stock rotation within the pharma basket. Nifty Pharma did not rise because every constituent advanced. Instead, the sector was led by a set of meaningful gainers, particularly Divi's Laboratories Ltd., Gland Pharma Ltd., and Zydus Lifesciences Ltd.. These gains helped counter weakness in stocks such as JB Chemicals & Pharmaceuticals Ltd., Granules India Ltd., and Cipla Ltd..

A useful way to interpret the session is to separate percentage movers from index influence. The strongest percentage gains came from Divi's Laboratories, Gland Pharma, and Zydus Lifesciences. At the same time, some heavyweight names were mixed. Sun Pharmaceutical Industries Ltd., Cipla Ltd., and Dr. Reddy's Laboratories Ltd. ended lower, while Divi's Laboratories, Mankind Pharma Ltd., and Zydus Lifesciences rose. That is exactly the kind of setup that can keep the sector index positive, but only modestly positive.

The opening pattern also matters. Nifty Pharma opened at 26,567, almost flat versus the previous close of 26,564. This shows there was no major overnight repricing in the sector. The day’s gain developed through intraday stock selection rather than through a big opening gap. When an index starts flat and still closes positive, it often suggests steady demand emerging after the open.

Another notable feature is that the top gainer, Divi's Laboratories, rose 3.21% and ended at 9,025 after trading as high as 9,043. Gland Pharma gained 2.78%, while Zydus Lifesciences rose 2.27%. These are strong moves for established pharma names and indicate focused interest within parts of the sector. On the other side, JB Chemicals & Pharmaceuticals fell 3.87%, the deepest decline among the listed constituents, which limited broader momentum.

So, if someone asks why Nifty Pharma is up today, the simplest factual answer is this: the sector rose because several major stocks posted meaningful gains, and those gains outweighed losses in other constituents. The move was led by select outperformers rather than a uniform rise across the board.

Market Breadth: How Broad Was the Rally?

Breadth Metric	Value
Advancing Stocks	11
Declining Stocks	9
Unchanged Stocks	0
Advance-Decline Ratio	1.22
Stocks in Green	55%
Stocks in Red	45%

Market breadth for Nifty Pharma was positive, but not overwhelmingly strong. Out of 20 constituents, 11 advanced and 9 declined. That gives the sector an advance-decline ratio of 1.22, meaning there were 1.22 advancing stocks for every declining stock. In practical terms, more stocks rose than fell, which supports the green close in the index, but the margin was narrow.

The 55% green and 45% red split tells the same story. This was not a broad-based surge where nearly every pharma stock participated. Instead, it was a selective session with a small edge to the gainers. Such breadth is often associated with a stable but stock-specific market rather than one driven by a strong sector-wide catalyst.

For traders and investors, this type of breadth has an important implication. When an index is up and breadth is positive but only moderately so, leadership matters a lot. That means it is useful to track which names are carrying the move, especially among heavyweight and active stocks. In today’s case, the gain was credible, but it depended meaningfully on stronger performers offsetting weakness elsewhere.

Complete Nifty Pharma Constituent Performance

Company	CMP	Today's %	Today's Change	52 Week High	52 Week Low	Trend
Divi's Laboratories Ltd.	9,025	3.21%	280.5	-	-	Strong bullish
Gland Pharma Ltd.	2,903.2	2.78%	78.6	-	-	Bullish
Zydus Lifesciences Ltd.	1,150	2.27%	25.5	-	-	Bullish
Glenmark Pharmaceuticals Ltd.	2,438.3	1.60%	38.3	-	-	Positive
Ipca Laboratories Ltd.	1,952.4	1.24%	23.9	-	-	Positive
Mankind Pharma Ltd.	2,393.7	1.21%	28.7	-	-	Positive
Laurus Labs Ltd.	1,887	1.11%	20.8	-	-	Positive
Abbott India Ltd.	26,555	0.53%	140	-	-	Mild positive
Lupin Ltd.	2,185	0.44%	9.5	-	-	Mild positive
Aurobindo Pharma Ltd.	1,623	0.32%	5.2	-	-	Mild positive
Biocon Ltd.	417.5	0.07%	0.3	-	-	Flat to positive
Ajanta Pharma Ltd.	3,551.8	-0.09%	-3.1	-	-	Flat to negative
Natco Pharma Ltd.	863.4	-0.33%	-2.85	-	-	Mild negative
Torrent Pharmaceuticals Ltd.	4,890	-0.85%	-42	-	-	Negative
Dr. Reddy's Laboratories Ltd.	1,182	-0.96%	-11.5	-	-	Negative
Sun Pharmaceutical Industries Ltd.	1,899.5	-1.17%	-22.5	-	-	Negative
Alkem Laboratories Ltd.	5,303.5	-1.20%	-64.5	-	-	Negative
Cipla Ltd.	1,402.7	-1.36%	-19.3	-	-	Negative
Granules India Ltd.	828.2	-2.10%	-17.75	-	-	Weak
JB Chemicals & Pharmaceuticals Ltd.	2,408.9	-3.87%	-97.1	-	-	Weakest

The complete constituent list confirms how mixed the session really was. The strongest performer was Divi's Laboratories with a gain of 3.21%, while the weakest was JB Chemicals & Pharmaceuticals with a decline of 3.87%. Between those two extremes sat a fairly even distribution of gainers and losers.

This matters because sector indices often hide internal dispersion. A positive close in Nifty Pharma does not mean every pharma stock had a strong day. Investors looking only at the index level might miss the fact that several well-known names, including Sun Pharma, Cipla, Dr. Reddy's Laboratories, and Torrent Pharmaceuticals, actually ended in the red.

Top Gainers in Nifty Pharma Today

Company	Price Change	% Change	Why It Mattered Today
Divi's Laboratories Ltd.	280.5	3.21%	Largest percentage gainer among the key advancing names and a major source of positive sector momentum.
Gland Pharma Ltd.	78.6	2.78%	Strong upside move added breadth to the rally and supported the index despite weakness in several peers.
Zydus Lifesciences Ltd.	25.5	2.27%	Solid advance among heavyweight names helped offset declines in other large constituents.
Glenmark Pharmaceuticals Ltd.	38.3	1.60%	Delivered additional support to the gainers’ side of the breadth equation.
Ipca Laboratories Ltd.	23.9	1.24%	Contributed to the positive close by adding to the list of mid-strength gainers.

Divi's Laboratories clearly stood out. A 3.21% gain in a prominent pharma stock can have a visible effect on overall sector tone, especially on a day when breadth is only moderately positive. Gland Pharma and Zydus Lifesciences then added further support, creating a cushion against weakness in some heavyweight counters.

The pattern among top gainers suggests that buying interest was concentrated rather than universal. That does not reduce the importance of the move; in fact, selective leadership can be an early sign of rotation within a sector. But it does mean investors should avoid reading the session as a blanket strength signal for every pharma stock.

Top Losers in Nifty Pharma Today

Company	Price Change	% Change	Why It Weighed on the Sector
JB Chemicals & Pharmaceuticals Ltd.	-97.1	-3.87%	Deepest decline in the basket, limiting the index’s upside.
Granules India Ltd.	-17.75	-2.10%	One of the sharpest falls among constituents, adding to the drag on breadth.
Cipla Ltd.	-19.3	-1.36%	Loss in a major constituent offset part of the gains from advancing stocks.
Alkem Laboratories Ltd.	-64.5	-1.20%	Added to the negative side of the session and reduced the strength of the overall finish.
Sun Pharmaceutical Industries Ltd.	-22.5	-1.17%	Weakness in a heavyweight name capped the index’s ability to close much higher.

The draggers list explains why Nifty Pharma gained only 0.23% despite several strong gainers. The sector’s weakest stock, JB Chemicals & Pharmaceuticals, fell almost 4%. Meanwhile, declines in Cipla and Sun Pharma mattered because these are closely watched names and can influence sentiment across the basket.

When both heavyweight and non-heavyweight stocks appear among the losers, the message is mixed rather than outright weak. That is exactly what today’s index close reflects: enough strength to finish in the green, but enough selling pressure to prevent a stronger breakout.

Heavyweight and Most Active Stocks

The available heavyweight list provides a useful lens for understanding index direction. Among these prominent names, the session was split. Divi's Laboratories rose 3.21%, Zydus Lifesciences gained 2.27%, Mankind Pharma added 1.21%, Lupin rose 0.44%, Abbott India gained 0.53%, and Aurobindo Pharma advanced 0.32%. On the other hand, Sun Pharma, Torrent Pharmaceuticals, Cipla, and Dr. Reddy's Laboratories closed lower.

This mix is important because sector indices are usually shaped by larger constituents. When a few influential stocks rise strongly, they can counterbalance moderate declines elsewhere. Today, that appears to have been the case. Divi's Laboratories was especially important because it combined strong percentage performance with heavyweight relevance.

The most active list mirrors the heavyweight names, which reinforces where attention was concentrated. Investors watching Nifty Pharma live would likely have focused on Sun Pharma, Divi's Laboratories, Torrent Pharmaceuticals, Cipla, Dr. Reddy's Laboratories, Mankind Pharma, and Zydus Lifesciences. These are the stocks that best explain the sector’s mixed but positive tone on the day.

Intraday Price Structure and Session Interpretation

Even without indicator-based technical readings, the available intraday data offers several useful signals. First, the index opened at 26,567 and closed at 26,626.3, which means it ended above the open. That generally indicates buyers retained some control by the end of trade. Second, the day’s high was 26,764.95 and the low was 26,437.15, showing that the sector experienced both selling pressure and recovery within the same session.

The low was below the previous close, so the sector did face intraday weakness. But the recovery back above the previous close suggests there was support on dips. That kind of action is commonly interpreted as constructive, especially when paired with positive breadth. However, because the close remained well below the day’s high, traders should still classify the move as moderate rather than aggressive.

The best way to describe today’s structure is sideways to mildly bullish. There was no large trend extension, but there was enough buying to absorb declines and keep the index in positive territory. The index was not in a weak close, and it was not in a runaway momentum phase either.

Historical Performance Context Using Available Data

Period	Level / Change	Interpretation
Today	26,626.3 (+62.3 / +0.23%)	Positive close with selective leadership
Previous Close	26,564	Base level for today’s move
Open vs Previous Close	26,567 vs 26,564	Near-flat opening
High vs Previous Close	26,764.95 vs 26,564	Intraday strength emerged after the open
Low vs Previous Close	26,437.15 vs 26,564	Temporary dip below prior close was bought into

The available historical comparison for this session shows a stable opening, a dip below the prior close, a recovery to an intraday high above 26,700, and a final close in the green. That path usually indicates a market that tested support but did not break down. For short-term observers, this is more encouraging than a session that opens strong and fades weakly into the close.

Because the index finished only modestly higher, today’s move should be viewed as incremental progress rather than a decisive trend event. The stronger signal came from the ability of gainers to absorb pressure from notable losers, not from the magnitude of the index gain alone.

What Investors Should Watch Next in Nifty Pharma

The next thing to watch is whether today’s leadership remains intact. If Divi's Laboratories, Gland Pharma, Zydus Lifesciences, Glenmark Pharmaceuticals, and other advancing names continue to hold gains or extend them, the sector may build on today’s positive close. If those leaders cool down while heavyweight losers remain weak, Nifty Pharma could slip back into a more neutral pattern.

Investors should also monitor whether the breadth improves from 11 gainers versus 9 losers to a more convincing spread. A stronger follow-through session would typically show broader participation across the constituent list, not just strength in a handful of stocks. In contrast, if the index remains positive while breadth narrows, that would suggest concentration risk within the sector move.

Heavyweight behavior remains critical. Sun Pharma, Cipla, Dr. Reddy's Laboratories, and Torrent Pharmaceuticals all ended lower today. If these names stabilize while top gainers continue to perform, the index could become more balanced and potentially stronger. But if the losers stay under pressure, then the burden of support will remain on a limited set of outperformers.

Finally, watch intraday structure. Another session that opens near flat, dips, and recovers would reinforce the idea that buying interest exists on declines. On the other hand, an inability to stay above the previous close after early strength would indicate that the current positive tone still lacks full conviction.

Key Takeaways

Nifty Pharma closed at 26,626.3, up 62.3 points or 0.23% on 26 August 2026.
The index opened nearly flat and stayed in a broad intraday range before ending modestly higher.
Market breadth was positive but mixed: 11 stocks advanced and 9 declined.
Divi's Laboratories Ltd. was the top performer, rising 3.21%.
JB Chemicals & Pharmaceuticals Ltd. was the biggest loser, falling 3.87%.
Heavyweight action was split, with gains in Divi's Laboratories, Zydus Lifesciences, and Mankind Pharma offsetting declines in Sun Pharma, Cipla, Dr. Reddy's Laboratories, and Torrent Pharmaceuticals.
The session looked sideways to mildly bullish rather than strongly trending.
The most important next signal is whether breadth broadens and whether heavyweight losers stabilize.

Published on 26 August 2026 at 4:05 PM IST

Frequently Asked Questions

1. What is Nifty Pharma today?

Nifty Pharma closed at 26,626.3 on 26 August 2026, up 62.3 points or 0.23% from the previous close of 26,564.

2. Why is Nifty Pharma up today?

Nifty Pharma rose because several key stocks, especially Divi's Laboratories, Gland Pharma, and Zydus Lifesciences, posted strong gains that outweighed declines in other constituents.

3. Was Nifty Pharma bullish or bearish today?

The session was mildly bullish. The index closed above both its opening level and previous close, although the gain was moderate and breadth was mixed.

4. What was the opening value of Nifty Pharma today?

Nifty Pharma opened at 26,567, which was almost unchanged from the previous close of 26,564.

5. What were the day high and day low of Nifty Pharma?

The index traded between a day high of 26,764.95 and a day low of 26,437.15.

6. How many Nifty Pharma stocks advanced today?

Eleven out of 20 Nifty Pharma constituents advanced, indicating slightly positive market breadth.

7. How many Nifty Pharma stocks declined today?

Nine constituents declined during the session, showing that the rally was selective rather than broad-based.

8. What is the advance-decline ratio of Nifty Pharma today?

The advance-decline ratio was 1.22, meaning there were 1.22 advancing stocks for every declining stock.

9. Which stock gained the most in Nifty Pharma today?

Divi's Laboratories was the top gainer, rising 3.21% to close at 9,025.

10. Which stock fell the most in Nifty Pharma today?

JB Chemicals & Pharmaceuticals was the top loser, declining 3.87% to close at 2,408.9.

11. Which heavyweight stocks influenced Nifty Pharma today?

Key heavyweight movers included Divi's Laboratories, Zydus Lifesciences, Mankind Pharma, Sun Pharma, Cipla, Dr. Reddy's Laboratories, and Torrent Pharmaceuticals.

12. What should investors watch next in Nifty Pharma?

Investors should watch whether today’s top gainers sustain momentum, whether heavyweight losers stabilize, and whether market breadth improves beyond the current 11-to-9 advance-decline split.

Disclaimer

Investments in securities markets are subject to market risks. Read all related documents carefully before investing. This sector-index update is for informational and educational purposes only and is not personalized investment advice or a recommendation to buy, sell, or hold any security.